InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: Whalatane post# 98243

Monday, 01/16/2017 6:39:20 PM

Monday, January 16, 2017 6:39:20 PM

Post# of 424028
K-

No insurance Co IMHO is going to pay all of the $14,000 a yr price tag for a PCSK9 drug that only lowers RRR by 15%.

??? When I said anything about Ins. Co approach re. PCSK9 ... Do you argue with yourself?

they will be paying all of the $2.808 ( your price ) for V / year

My price ??? Check Amarin IR presentation. Furthermore: When I said, Ins. Co.s are paying this price? ... you said it ...

lower co pays for secondary prevention , higher co pays for primary prevention... and again...depending on the degree of risk reduction.

- ">140 million lives covered by payers on tier 2 unrestricted". As I understand T2 is the best available Tier, since T1 is for generics ... I do not expect that any payer will move V into higher tier if RRR will be 15% ... the opposite will happen, a lot of Co. will mone it down into the best available Tier
- please enlighten me: how many drug has more than one Tier (within a same plan) for different usage? How do you mean? e.g. T2 for secondary prevention and T3/4 for primary prevention within the same plan, for the same patient ... I do not think ...
- again ... co pay is depending on Tier ...

Best,
G

#STRONGERTOGETHER

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News